Clostridium Difficile Infection (C-Diff)


Active/Enrolling:

ROAR

  • Principal Investigator: Gary Wang, MD, PhD
  • Link: https://clinicaltrials.gov/study/NCT05835219
  • Purpose: The goal of this outpatient study is to collect data on patients with recurrent C. difficile infection that have been treated with REBYOTA, a fecal microbiota suspension. This observational study aims to describe the effectiveness of treatment with REBYOTA and patient-reported outcomes. 
  • Contact: Evan Waters, 352-294-5885, waterse@ufl.edu

Closed to Enrollment:

None at this time; please check back soon.

Pending:

None at this time; please check back soon.

Completed:

Rebiotix

  • Principal Investigator: Gary Wang, MD, PhD
  • Link: https://clinicaltrials.gov/study/NCT02589847
  • Purpose: This study will evaluate the safety and efficacy of RBX2660, a microbiota suspension, combined with antibiotics in the treatment of recurring C. difficile infection. Patients who have had at least two recurrences after a primary episode and have completed at least two rounds of antibiotics, or who have had at least two episodes of severe C. difficile infection resulting in hospitalization may be eligible for this study. 
  • Contact: Evan Waters, 352-294-5885, waterse@ufl.edu